Tissue Therapies patent accepted in Australia
Tuesday, 31 May, 2005
The core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia.
The acceptance follows the granting of the core VitroGro patent in New Zealand in March, the first jurisdiction to do so.
Tissue Therapies has worldwide exclusive rights to commercialise VitroGro under an IP Agreement with the Queensland University of Technology, and will also seek core patents for VitroGro in other jurisdictions such as the USA, Canada, Europe, South Korea, China and Japan.
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
